Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Oropharyngeal Neoplasms 1Neurofibromatosis 1 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Learning Disabilities 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Dyslexia 1Carcinoma 1Breast Neoplasms 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Lovastatin × 1 year × Clear all
NCT07619365 2026-06-02

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Washington University School of Medicine

Phase 2 Not yet recruiting
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡